Participated · Series B · Nov 2019

Huma is a London-based global healthcare AI company led by founder and CEO Dan Vahdat. It provides a modular, cloud-agnostic platform offering no-code configuration of regulated disease management tools, a library of pre-built modules, device connectivity, APIs, and a marketplace. The platform can host and deploy diagnostic and predictive AI algorithms and supports integrations to advance digital-first care and research. Huma's platforms are used by more than 3,000 hospitals and clinics, with over 35 million screened users, 4 million registered healthcare users, and support for over 800 studies covering about 1 million participants. With this Series D, the company is launching the Huma Cloud Platform, a technology ecosystem to support its digital health initiatives and enable others to launch and scale projects. Huma intends to use the funds to expand operations and its business reach and has now raised over $300 million to date. Huma offers a modular platform that supports digital 'hospitals at home' and decentralized clinical trials by combining real‑time smartphone and wearable data, predictive algorithms, digital biomarkers, and real‑world data. Its app lets clinicians monitor patients' symptoms and vital signs remotely and supports medical research and virtual trials. The company says its 'hospital at home' solution was deployed across 100+ clinics in Germany in a single day. Huma has raised more than $200 million in venture funding to date from backers including Bayer, Samsung and Sony. Founded in 2011 as Medopad by Dan Vahdat and Rich Khatib, Huma says the coronavirus pandemic accelerated progress on its virtual trials. The company plans further U.S. expansion and to act as an extended digital‑health arm for partners such as AstraZeneca. Huma Therapeutics operates a predictive healthcare platform that combines a proprietary predictive algorithm, biomarkers, and real-world data to deliver modular 'hospital at home' services and enable decentralized clinical trials. Its platform is reported to double clinical capacity and reduce hospital readmission rates by one-third. The company plans to scale its 'hospitals at home' offering in the UK and to support large decentralized clinical trials for pharmaceutical and research customers across the US, Asia, and the Middle East. The recent funding is intended to accelerate product rollout and research efforts. Huma was founded in 2011 by Dan Vahdat and Rich Khatib. Medopad builds AI-based methods to create and track digital biomarkers using apps, wearables and advanced sensors, working with pharmaceutical and tech partners to deliver end-to-end solutions. The company is developing biomarkers and therapeutics related to heart health in collaboration with Bayer and is also working on diagnostics for Parkinson’s, Alzheimer’s and diabetes. Medopad has partnerships with Tencent for AI engine development and with teaching hospitals (including the Royal Hospital, Wolverhampton) for clinical trials such as tracking aortic stenosis. It is collaborating with Janssen on at-home cognitive tests to track early signs and progression of Alzheimer’s. Medopad emphasizes that patient data is collected with consent, anonymized when shared, and does not leave the country where it is collected; the company positions its algorithms and methods as its primary asset. Last year it signed deals totaling about $140 million with a group of Chinese firms, including Tencent, Ping An, and Chinese divisions of GSK and Johnson & Johnson. Medopad provides a platform for data capture and to improve communication between patients and healthcare professionals, powered by AI and machine learning to encourage proactive care and earlier detection. The company is London-based and says its technology helps make more people proactive and improve early detection rates. Medopad reports 400% year‑on‑year growth in the value of its projects since 2015. It has partnerships with technology and healthcare organisations including Tencent, HP, the NHS and Johns Hopkins University, and has secured about £100 million in partnership deals with companies including Tencent. Medopad plans to use new funding for global growth and intends to create 500 new jobs in the UK by 2020. The business has also appointed Stuart Fletcher (former BUPA CEO) and Simon MacKinnon (chairman of Sinophi Healthcare) as non-executive directors.

Participated · Series B · Jan 2018

NurseGrid operates a staffing and scheduling technology platform designed exclusively for nurses, helping hospitals manage schedules, open shifts, float pools, and recruiting. The platform aims to fill empty shifts and improve nurse retention amid a nationwide nursing shortage. CEO and founder Joe Novello is a longtime nurse and leads product direction. The company said it will use the new funds to further develop the platform and add features, and has "big plans for 2018." NurseGrid reported its team nearly doubled to 34 employees and its mobile app has nearly half a million downloads. The company also cited that 85 percent of nurses said departments using the technology made them more satisfied and less likely to look for other work. To date NurseGrid has raised $9.3 million in total funding.

Participated · Seed · Mar 2016

Cubii is a Chicago-based maker of an under-desk elliptical trainer that first gained traction on Kickstarter. The campaign raised nearly $300,000 against an $80,000 goal and the device has been purchased by more than 3,000 people. The company sells primarily online through its website and Kickstarter but plans a B2B push to sell units in bulk to offices. Cubii intends to use new funding to keep up with product demand and increase marketing efforts. CEO Arnav Dalmia says the startup is generating enough sales to keep the business alive and does not plan another round in the near term. The company is positioning itself to convert its crowdfunding success into a sustainable operational business.

Participated · Series A · Jun 2015

Tute Genomics offers a cloud-based genome interpretation platform that delivers analytics, interpretation and reporting for clinical sequencing to support predictive, preventive and precision medicine. The platform is positioned for healthcare use and aims to enable genomics-driven clinical decision-making. The company is led by Reid Robison, MD MBA (CEO) and Kai Wang, PhD (President and Chairman). Tute Genomics is based in Provo, Utah. The article reports the company recently closed a financing round (see deal details). No operating metrics were provided in the article. Tute Genomics has developed a comprehensive cloud-based genome analytics platform that helps clinicians and researchers draw meaningful insights from genome sequencing data. The company processes sequencing data in the cloud and has commercially deployed its platform across clinical labs, molecular diagnostic companies and research institutions. Nearly 10,000 samples have been processed on the platform to date. Tute plans to use the new funding to expedite genetic discoveries and enable the adoption of genomic medicine in everyday clinical care. The company is led by Reid Robison, MD MBA, CEO, and Kai Wang, PhD, President. Tute Genomics builds a cloud-based genome interpretation platform that uses proprietary machine-learning algorithms to rapidly prioritize clinically relevant genetic variants, genes and pathways. The platform supports discovery of novel disease genes and identification of predictive biomarkers. Its analysis now includes over 90 annotation types, scoring methods and genetic databases. The company is led by CEO Reid J. Robison, MD MBA, and President Dr. Kai Wang, and participated in the BoomStartup accelerator in Utah. Tute raised $1.5M in seed funding from a group of backers and additionally raised approximately $300K via AngelList's Syndicate. The company intends to use the funds to further develop its software.

Participated · Seed · Apr 2015

PlateJoy offers a personalized meal-kit/recipe service that generates queues of healthy, at-home meals tailored to users' weight, height, dietary preferences (vegan/vegetarian) and weight-loss goals. The core product is a personalization process that customizes meals and portion sizes to individual needs. Founder Christina Bognet launched PlateJoy after graduating from MIT and losing 50 pounds, citing poor quality and high cost among existing diet delivery services. The company plans to expand into bigger markets and compete with larger meal-kit players like Blue Apron by emphasizing healthier options. Most of the seed funding will be used to expand PlateJoy's personalization tool and to hire developers, marketers, and designers to further customize the site. PlateJoy raised $1.7 million in seed funding and remains smaller than competitors such as Blue Apron, which the article notes delivers over 2 million meals a month and has $58 million in the bank with a $60 million revenue run rate.